Literature DB >> 15542166

Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma.

S Muschitz1, P Petrow, E Briot, C Petit, R De Crevoisier, P Duvillard, P Morice, C Haie-Meder.   

Abstract

BACKGROUND AND
PURPOSE: This study correlates the treated volume, the GTV and the CTV at the time of intracavitary brachytherapy (BT) with the histopathological findings obtained by surgery (S) in 33 patients (pts) with cervix carcinoma. PATIENTS AND METHODS: Sixteen pts (group I), FIGO stage IB1 (1), IB2 (4), IIB (10), IIIB (1), received external beam radiotherapy (EBT) with a total dose of 45 Gy in 5 weeks and concomitant CISPLATIN 40 mg/m(2) weekly, followed by BT up to a total dose of 15 Gy. S was performed 6-8 weeks thereafter. Seventeen pts (group II), FIGO IA2 (1), IB1 (14), IIB (2), were treated by BT alone with a total dose of 60 Gy and S after 6-8 weeks. All pts had a MRI examination after BT with a moulded applicator in situ for exact delineation of GTV, CTV and critical organs and a 3D dosimetry directly from MRI data.
RESULTS: In group I (EBT + BT + S), the histopathological findings showed complete tumour sterilization (CR) in 56% of pts. Residual disease (RD) was found in 43%. Dosimetric data showed in pts with CR a larger mean treated volume (213 vs. 166 cm(3)) and a better mean coverage of the GTV and the CTV by the reference isodose (99 and 91%) as in pts with RD (85 and 77%). In group II (BT + S), CR was found in 52%, RD in 41%. Dosimetric data showed a larger mean treated volume (154 vs. 109 cm(3)) for pts with RD and a mean coverage of the GTV and the CTV by the reference isodose of 97 and 84% vs. 89 and 80% for pts with CR.
CONCLUSIONS: An incomplete coverage of the GTV and/or the CTV by the reference isodose is an important risk factor for RD at the time of surgery. Furthermore, for pts who received BT alone, tumour size seemed to be a limiting factor for an accurate coverage of the CTV by the reference isodose.

Entities:  

Mesh:

Year:  2004        PMID: 15542166     DOI: 10.1016/j.radonc.2004.07.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  MRI-based pre-planning in patients with cervical cancer treated with three-dimensional brachytherapy.

Authors:  M Dolezel; K Odrazka; J Vanasek; T Kohlova; T Kroulik; K Kudelka; D Spitzer; M Mrklovsky; M Tichy; J Zizka; L Jalcova
Journal:  Br J Radiol       Date:  2011-09       Impact factor: 3.039

2.  Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study.

Authors:  Julia Vízkeleti; Ildikó Vereczkey; Georgina Fröhlich; Szilvia Varga; Katalin Horváth; Tamás Pulay; Imre Pete; Csaba Nemeskéri; Árpád Mayer; Norbert Sipos; Miklós Kásler; Csaba Polgár
Journal:  Pathol Oncol Res       Date:  2014-07-11       Impact factor: 3.201

3.  Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study.

Authors:  Philip Chan; Inhwan Yeo; Gregory Perkins; Anthony Fyles; Michael Milosevic
Journal:  Radiat Oncol       Date:  2006-05-04       Impact factor: 3.481

4.  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy.

Authors:  Johannes C A Dimopoulos; Peter Petrow; Kari Tanderup; Primoz Petric; Daniel Berger; Christian Kirisits; Erik M Pedersen; Erik van Limbergen; Christine Haie-Meder; Richard Pötter
Journal:  Radiother Oncol       Date:  2012-01-30       Impact factor: 6.280

5.  Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma.

Authors:  Ning Wu; Zhipeng Zhao; Dongmei Han; Guanghui Cheng; Hongfu Zhao
Journal:  J Radiat Res       Date:  2019-01-01       Impact factor: 2.724

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.